SCHEMBL9361815

SCHEMBL9361815

CCN(CC)c1ccc(C=O)c(OC(C)=O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
MAPT P10636 8/20 0.48
KDM4E B2RXH2 5/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
HPGD P15428 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH3A1 P30838 1/20 0.46
ALDH1A3 P47895 1/20 0.46
GAA P10253 1/20 0.44
BACE1 P56817 4/20 0.43
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAOB P27338 1/20 0.41
CYP2C19 P33261 1/20 0.41
ATM Q13315 1/20 0.41
CRHBP P24387 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8415573 0.88 ALDH1A1 (0.56) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL8415313 0.87 ALDH1A1 (0.54) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL7598406 0.86 ALDH1A1 (0.56) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL7863602 0.84 ALDH1A1 (0.65) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL28338105 0.84 ALDH1A1 (0.65) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL10425633 0.83 ALDH1A1 (0.49) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL22587845 0.83 ALDH1A1 (0.46) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL2950989 0.83 ALDH1A1 (1.00) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL1646997 0.82 ALDH1A1 (0.62) ALDH1A1L3MBTL1MAPTKDM4EKMT2A
SCHEMBL7521809 0.82 ALDH1A1 (0.48) ALDH1A1L3MBTL1MAPTKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419206-B1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (ES) 2025-09-17 EP disclosed
US-20240415825-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA Fundación Privada Instituto De Salud Global Barcelona (ES) 2024-12-19 US disclosed
EP-4419206-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA Fundacio Institut de Bioenginyeria de Catalunya (ES) 2024-08-28 EP disclosed
WO-2023067170-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) 2023-04-27 WO disclosed
WO-2013068592-A1 INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE FONDATION JEROME LEJEUNE (FR) 2013-05-16 WO disclosed
WO-2013068592-A1 INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE FONDATION JEROME LEJEUNE (FR) 2013-05-16 WO disclosed
EP-0326133-B1 Organic nonlinear optical material and nonlinear optical device NIPPON TELEGRAPH & TELEPHONE (JP) 1994-12-07 EP disclosed
US-4999139-A Aminonitrostyrene Compound; Including a Polarizer, an Optical Resonator an a Reflector NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) 1991-03-12 US disclosed
US-4997595-A Organic nonlinear optical material and nonlinear optical device NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) 1991-03-05 US disclosed
EP-0326133-A2 Organic nonlinear optical material and nonlinear optical device NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) 1989-08-02 EP disclosed
EP-0016418-B1 WATER-INSOLUBLE IMINO COUMARIN DYESTUFFS, PROCESS FOR THEIR PREPARATION AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-16 EP disclosed
EP-0016418-A1 Water-insoluble imino coumarin dyestuffs, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1980-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240415825-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA ABAT, GLS2, CPS1 ALDH1A1 2819/4885L3MBTL1 916/4885MAPT 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.